Facebook Instagram Twitter RSS Feed Back to top

The list of international projects SAS

Centre of Experimental Medicine SAS
Anti-inflammatory effect of astaxanthin, sulforaphane and Crocus sativus extract evaluated in two rodent models of age related diseases.
-
Program: Inter-academic agreement
Project leader: PharmDr. Bauerová Katarína PhD., DrSc.
Duration: 1.1.2018 - 31.12.2021
EU-NETVAL International Thyroid Validation Study
EU-NETVAL Medzinárodná validačná štúdia tyroidnej disrupcie
Program: Multilateral - other
Project leader: Dr.rer.nat., Ing. Kanďárová Helena ERT
Annotation:Characterising, validating and standardising new non-animal methods and approaches are important steps towards their regulatory use and international adoption. Various thyroid methods, targeting different modes of action of thyroid disruption, are currently under validation by EURL ECVAM and its network of validation laboratories EU-NETVAL. Chemicals that disrupt thyroid homeostasis have the potential to be endocrine disruptors and thus associated with several adverse health effects. About EU-NETVAL: EU-NETVAL is a large network of 39 highly qualified test facilities across Europe, coordinated by the JRC to support the in vitro method validation process. It represents a wide range of expertise and competences and includes laboratories experienced in advanced in vitro procedures, biological test systems and measurement techniques.
Duration: 1.1.2021 - 1.1.2023
Catalysing transcriptomic research in cardiovascular disease
Katalýza transkriptomického výskumu kardiovaskulárnych ochorení
Program: COST
Project leader: doc. RNDr. Barteková Monika PhD.
Annotation:This Action aims to create an interdisciplinary network to accelerate the understanding of transcriptomics in cardiovascular disease (CVD) and further the translation of experimental data into usable applications to improve personalized medicine in this field. CVD remains the leading cause of death worldwide and, despite continuous advances, better diagnostic and prognostic tools, as well as therapy, are needed. The human transcriptome, which is the set of all RNA produced in a cell, is much more complex than previously thought and the lack of dialogue between researchers and industrials and consensus on guidelines to generate data make it harder to compare and reproduce results. Currently, there is no network to address the complexity of transcriptomics in CVD, offering an advantage to this Action. It aims to provide opportunities for collaboration between stakeholders from complementary backgrounds, allowing the functions of different RNAs and their interactions to be more rapidly deciphered in the cardiovascular context for translation into the clinic. This Action will generate grant proposals to advance understanding of the transcriptome’s role in CVD and to translate findings into clinical applications, thus fostering personalized medicine and meeting a current public health challenge. CardioRNA will refine guidelines for transcriptomics investigations in CVD to increase reproducibility of results, facilitating clinical product development. It will disseminate knowledge and allow capacity-building through different types of meetings, prioritizing students and early career investigators. Thus, this Action will advance studies on cardiovascular transcriptomics, generate innovative projects and consolidate the leadership of European research groups in the field.
Duration: 3.10.2018 - 2.10.2022
Molecular logic lab-on-a-vesicle for intracellular diagnostics
Molecular logic lab-on-a-vesicle for intracellular diagnostics
Program: Horizon 2020
Project leader: RNDr. Mach Mojmír PhD.
Annotation:A dysfunction of cells lining the inner walls of blood vessels, i.e. the endothelium, is the primary cause of many lifestyle related diseases. According to the WHO, those diseases accounted for 60% of all deaths worldwide in 2005. Tailor-made diagnostic tools for early and reliable identification of endothelial dysfunction are urgently needed both in fundamental research and clinical routine, respectively. The Marie Skłodowska-Curie action LOGIC LAB objects to develop and characterize innovative molecular logic gates that can be applied as advanced diagnostic tools for parallel analyte sensing in live mammalian cells. Thereby, providing a unique method to discover endothelial dysfunction and the onset of diseases much easier and earlier than so far. LOGIC LAB creates a multi-faceted and multi-sectoral research environment for the next generation of scientists in order to establish a novel type of molecular logic sensors that reliably operate in biological media – a crucial requirement for their application i.e. as rapid and easy-to-handle tools for intracellular diagnostics. With excellent cross-disciplinary scientific and complementary training provided in the network, we aim to educate highly-skilled young scientists in the fields of chemistry, physics and biology, who will significantly strengthen the international research community in the domain of molecular logic sensing. Thus, in the long term, LOGIC LAB aims to finally bridge the gap between lab bench and biological or medical practice. It is this gap, that so far prevents a wide-ranging use of existing molecular logic gates e.g. for the diagnosis of lifestyle-associated diseases.
Duration: 1.11.2018 - 31.10.2022
Anti-inflammatory effects of natural compounds isolated from Vietnam medicinal plants
Protizápalový účinok prírodných látok izolovaných z vietnamských liečivých rastlín
Program: Bilateral - other
Project leader: PharmDr. Bauerová Katarína PhD., DrSc.
Duration: 1.1.2020 - 31.12.2022
Realising the therapeutic potential of novel cardioprotective therapies
Realizácia terapeutického potenciálu nových kardioprotektívnych terapií
Program: COST
Project leader: MUDr. Ravingerová Táňa DrSc., FIACS
Annotation:The proposed COST Action will set up a pan-European Research Network of leading experts in cardioprotection, to jointly develop new initiatives and new strategies for finding innovative and more effective approaches to cardioprotection and for optimizing the pre-clinical and clinical evaluation of new cardioprotective therapies, so as to improve their translation into the clinical setting for patient benefit. The COST Action will co-ordinate and strengthen European research in the field of cardioprotection and accelerate scientific progress through the dissemination and sharing of new therapeutic targets, among network members and industrial partners, thereby facilitating the discovery of new cardioprotective therapies. By utilizing the joint expertise of different European network members we will investigate factors which confound the efficacy of new cardioprotection therapies including comorbidities (such as age, diabetes, and hypertension) and co-medications (such as anti-platelet therapies, statins and beta-blockers). Finally, we will set up a European network of research centers for multi-center laboratory testing of new cardioprotective therapies using small and large animal models of acute IRI in order to select those therapies most likely to succeed in the clinical setting. All aspects of this COST Action proposal require a critical mass of partners across a wide geographic distribution across Europe in order to deliver the objectives outlined in this proposal. The discovery of novel signaling pathways and targets underlying cardioprotection both within and outside the cardiomyocyte (WG1 NEW TARGETS), and the testing of different combinations of cardioprotective therapy (WG2 COMBINATION THERAPY) requires investigators with different experience and expertise across Europe. The ability to test the effect of confounders of cardioprotection (WG3 CONFOUNDERS) requires the expertise of different partners in the different co-morbidities and testing of co-medications. Finally, the most important objective of this COST Action proposal, requires the setting up of a Europe-wide research network for (a) multicenter testing of novel cardioprotective therapies using small and large animal models (WG4 CONSORTIUM) and (b) testing of novel cardioprotective therapies in proof-of-concept clinical studies and optimization of multi-center clinical outcome cardioprotection studies. By definition this requires a critical mass of research partners distributed across Europe.
Duration: 19.10.2017 - 18.10.2021
Collaboration on a complex pharmacological assessment of inflammatory diseases of the musculo-skeletal system and gastrointestinal tract on experimental animal models
Spolupráca na komplexnom hodnotení farmakologického ovplyvnenia zápalových ochorení pohybového aparátu a gastrointestinálneho traktu na experimentálnych zvieracích modeloch
Program: Bilateral - other
Project leader: PharmDr. Bauerová Katarína PhD., DrSc.
Duration: 1.1.2019 - 31.12.2021
Training Network for improving of safety of medical devices - focus on oral cavity
Školiaca sieť zameraná na zvýšenie bezpečnosti zdravotníckych pomôcok - fokus na ústnu dutinu
Program: Multilateral - other
Project leader: Dr.rer.nat., Ing. Kanďárová Helena ERT
Annotation:The TraiN-SafeMDs (i.e. Training Network for improving knowledge on the safety of medical devices) project brings together the unique expertise of the Czech National Institute of Public Health located in Prague (NIPH), the expertise of the Centre of Experimental Medicine in Bratislava (CEM) and the Austrian Institute of Technology in Vienna (AIT). The research team of the project has extensive expertise in tissue engineering of models of oral epithelium and/or in safety testing of different MD materials. The project also aims into the training of PhD students and early career scientist in the use of in vitro methods for the safety assessment of MDs.
Duration: 1.1.2020 - 31.8.2022
Ontology-driven and artificial intelligence-based repeated dose toxicity testing of chemicals for next generation risk assessment
Testovanie opakovanej toxicity chemických látok na základe ontológie a umelej inteligencie za účelom hodnotenia rizík metódami NGRA
Program: Horizon 2020
Project leader: Dr.rer.nat., Ing. Kanďárová Helena ERT
Annotation:The vision of the ONTOX project is to provide a functional and sustainable solution for advancing human risk assessment of chemicals without the use of animals in line with the principles of 21st century toxicity testing and next-generation risk assessment. Specifically, ONTOX will deliver a generic strategy to create innovative new approach methodologies (NAMs) in order to predict systemic repeated dose toxicity effects that, upon the combination with tailored exposure assessment, will enable human risk assessment. This strategy can be applied to any type of chemical and systemic repeated dose toxicity effect. However, for proof-of-concept purposes, focus will be put on 6 specific NAMs addressing adversities in the liver (steatosis and cholestasis), kidneys (tubular necrosis and crystallopathy) and developing brain (neural tube closure and cognitive function defects) induced by a variety of chemicals, including from the pharmaceutical, cosmetics, food and biocide sectors. The 6 NAMs will each consist of a computational system based on cutting-edge artificial intelligence (AI) and will be primarily fed by available biological/mechanistic, toxicological/ epidemiological, physico-chemical and kinetic data. Data will be consecutively integrated in physiological maps, quantitative adverse outcome pathway networks and ontology frameworks. Data gaps, as identified by AI, will be filled by targeted state-of-the-art in vitro and in silico testing. The 6 NAMs will be evaluated and applied in collaboration with industrial and regulatory stakeholders in order to maximise end-user acceptance and regulatory confidence. This is anticipated to expedite implementation in risk assessment practice and to facilitate commercialisation. ONTOX will have a deep and long-lasting impact at many levels, in particular by consolidating Europe's world-leading position regarding the development, exploitation, regulation and application of animal-free methods for human risk assessment of chemicals.
Duration: 1.5.2021 - 1.5.2026

The total number of projects: 9